10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-VHL / Von Hippel Lindau Antibody (aa167-179)

Goat Anti Human Polyclonal Antibody
Catalog # ALS17856

Product Information

Application	WB, IHC-P, E
Primary Accession	P40337
Predicted	Human, Mouse, Rat, Rabbit, Monkey, Dog
Host	Goat
Clonality	Polyclonal
Calculated MW	24153
Concentration (mg/ml)	0.5 mg/ml

Additional Information

Gene ID	7428
Alias Symbol	VHL
Other Names	VHL, Elongin binding protein, HRCA1, RCA1, VHL1, Von Hippel-Lindau syndrome, Protein G7, PVHL
Target/Specificity	Human VHL. This antibody is expected to recognise both reported isoforms (NP_000542.1 and NP_937799.1).
Reconstitution & Storage	Immunoaffinity purified
Precautions	Anti-VHL / Von Hippel Lindau Antibody (aa167-179) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	VHL
Function	Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex (PubMed:10944113, PubMed:17981124, PubMed:19584355). Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions (PubMed:10944113, PubMed:17981124). Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases (PubMed:10944113, PubMed:17981124). Ubiquitinates, in an oxygen-responsive manner, ADRB2 (PubMed:19584355). Acts as a negative regulator of mTORC1 by promoting ubiquitination and degradation of RPTOR (PubMed:34290272).
Cellular Location	[Isoform 1]: Cytoplasm. Cell membrane; Peripheral membrane protein. Endoplasmic reticulum. Nucleus. Note=Found predominantly in the

	cytoplasm and with less amounts nuclear or membrane-associated (PubMed:9751722) Colocalizes with ADRB2 at the cell membrane (PubMed:19584355)
Tissue Location	Expressed in the adult and fetal brain and kidney.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.